Aberrant EGFR signaling mechanisms, including the overexpression of ligands and receptors, EGFR gene amplification, and activating mutations, have been shown in a number of cancers, such as non-small-cell lung cancer, colorectal carcinoma, breast cancer, and head and neck squamous cell carcinoma [22]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.